Use of Axillary Ultrasound to Guide Breast Cancer Management in the Genomic Assay Era

Use of Axillary Ultrasound to Guide Breast Cancer Management in the Genomic Assay Era: A Retrospective Cohort Study

The investigators aimed to determine if axillary ultrasound can reliably distinguish between patients with limited or high nodal burden, so that the patients with limited nodal burden can potentially avoid chemotherapy and instead receive upfront surgery followed by gene assay testing.

Inclusion Criteria:

• breast cancer patients with T1-3, HR-positive and HER2-negative disease.
• aged≥ 50 years old
• had axillary ultrasound prior to operation
• axillary lymph node dissection

Exclusion Criteria:

• Patients with neoadjuvant chemotherapy
• bilateral cancers